Colorectal Cancer and Its Microenvironment: A Brief Review DOI Creative Commons
Nauryzbay Imanbayev,

Arip Koyshybaev,

Nurgul Kereyeva

et al.

Medical Journal of the Islamic Republic of Iran, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 20, 2024

The narrative review aims to explore CRC pathogenesis by deciphering genetic-environmental interactions, analyzing the tumor microenvironment's role, and assessing treatment responses. These objectives seek enhance clinical decision-making improve patient care through a comprehensive understanding of disease. A from 2019 2024 on colorectal cancer (CRC) strategies was conducted. Systematic literature searches were performed PubMed, using CRC-related keywords ("Colorectal Neoplasms"[Mesh]) AND "Tumor Microenvironment"[Mesh]. Screening yielded 233 eligible studies, with 14 highly relevant ones included. PRISMA guidelines followed for transparency reproducibility. This spanning 2019-2024 shows diverse study designs (5 4 randomized controlled trials, 2 cohort 3 systematic reviews) varied sample sizes (from 4000 participants). Genetic mutations like KRAS BRAF are significant in pathogenesis, 8% exhibiting MMR proficiency. Immune cells paracrine signaling influential, therapeutic responses vary, limited efficacy reported certain combinations. highlights CRC's multifactorial nature complex dynamics. Integrating genetic, environmental, immune factors, personalized therapies pivotal efficacy. Continued research is crucial optimizing treatments improving outcomes, emphasizing need multifaceted, patient-tailored approaches management.

Language: Английский

Cancer immunotherapy and its facilitation by nanomedicine DOI Creative Commons
Chao Sui,

Heqing Wu,

Xinxin Li

et al.

Biomarker Research, Journal Year: 2024, Volume and Issue: 12(1)

Published: Aug. 3, 2024

Abstract Cancer immunotherapy has sparked a wave of cancer research, driven by recent successful proof-of-concept clinical trials. However, barriers are emerging during its rapid development, including broad adverse effects, lack reliable biomarkers, tumor relapses, and drug resistance. Integration nanomedicine may ameliorate current immunotherapy. Ultra-large surface-to-volume ratio, extremely small size, easy modification surface nanoparticles enable them to selectively detect cells kill in vivo. Exciting synergistic applications the two approaches have emerged treating various cancers at intersection nanomedicine, indicating potential that combination these therapeutic modalities can lead new paradigms treatment cancer. This review discusses status explores possible opportunities platform make more powerful precise synergizing approaches.

Language: Английский

Citations

5
Tumor microbiome: roles in tumor initiation, progression, and therapy DOI Creative Commons

Shengxin Zhang,

Jing Huang,

Z. X. Jiang

et al.

Molecular Biomedicine, Journal Year: 2025, Volume and Issue: 6(1)

Published: Feb. 8, 2025

Abstract Over the past few years, tumor microbiome is increasingly recognized for its multifaceted involvement in cancer initiation, progression, and metastasis. With application of 16S ribosomal ribonucleic acid (16S rRNA) sequencing, intratumoral microbiome, also referred to as tumor-intrinsic or tumor-resident has been found play a significant role microenvironment (TME). Understanding their complex functions critical identifying new therapeutic avenues improving treatment outcomes. This review first summarizes origins composition these microbial communities, emphasizing adapted diversity across diverse range types stages. Moreover, we outline general mechanisms by which specific microbes induce including activation carcinogenic pathways, deoxyribonucleic (DNA) damage, epigenetic modifications, chronic inflammation. We further propose may evade immunity promote angiogenesis support while uncovering influences on each step metastatic cascade, such invasion, circulation, seeding secondary sites. Additionally, closely associated with drug resistance efficacy modulating immune responses, metabolism, apoptotic pathways. Furthermore, explore innovative microbe-based strategies, engineered bacteria, oncolytic virotherapy, other modalities aimed at enhancing immunotherapeutic efficacy, paving way microbiome-centered frameworks.

Language: Английский

Citations

0
Liver Transplantation for Non-Hepatocellular Carcinoma: Role of Immune Checkpoint Inhibitors DOI

Pegah Bahrami,

Mohammad Al Zein,

Ali H. Eid

et al.

Journal of Clinical and Experimental Hepatology, Journal Year: 2025, Volume and Issue: unknown, P. 102558 - 102558

Published: March 1, 2025

Language: Английский

Citations

0
Genomic biology and therapeutic strategies of liver metastasis from gastric cancer DOI
Yichao Wang, Guangyu Ding,

Chu Chu

et al.

Critical Reviews in Oncology/Hematology, Journal Year: 2024, Volume and Issue: 202, P. 104470 - 104470

Published: Aug. 6, 2024

Language: Английский

Citations

2
Immunotherapy in Colorectal Cancer: Statuses and Strategies DOI Creative Commons
Yuan Li,

Zewei Cheng,

Shengli Li

et al.

Heliyon, Journal Year: 2024, Volume and Issue: 11(1), P. e41354 - e41354

Published: Dec. 19, 2024

Language: Английский

Citations

1
Advances in the therapeutic study of oncolytic virus in colorectal cancer DOI Creative Commons
Junjie Chen,

Kailang Chen,

Xianglin Yuan

et al.

Oncology and Translational Medicine, Journal Year: 2024, Volume and Issue: 10(4), P. 171 - 177

Published: July 2, 2024

Abstract Colorectal cancer (CRC) represents a considerable global health challenge, ranking third in incidence and second mortality worldwide. However, existing therapies for diseases with advanced stages often fail, thereby necessitating the search more comprehensive treatments. Oncolytic virus, novel anticancer approach, exhibits promising capabilities selectively targeting destroying tumor cells while augmenting their efficacy through genetic engineering modifications. Anticipated as new therapeutic paradigm CRC, this study aimed to assess performance of oncolytic virus clinical trials explore potential synergies other modalities, offering insights into future direction CRC treatment.

Language: Английский

Citations

1
The role of cell cycle-related genes in the tumorigenesis of adrenal and thyroid neuroendocrine tumors. DOI Creative Commons

Elena Filipovich,

Ekaterina Gorodkova,

Anastasia Shcherbakova

et al.

Heliyon, Journal Year: 2024, Volume and Issue: 11(1), P. e41457 - e41457

Published: Dec. 25, 2024

Language: Английский

Citations

1
Design of a deep-learning-based holographic diagnosis and treatment electromechanical vision system for traditional Chinese medicine DOI

Wenyi Zhang,

xiaofei xu,

Jiayi Wang

et al.

Published: July 5, 2024

Language: Английский

Citations

0
Colorectal Cancer and Its Microenvironment: A Brief Review DOI Creative Commons
Nauryzbay Imanbayev,

Arip Koyshybaev,

Nurgul Kereyeva

et al.

Medical Journal of the Islamic Republic of Iran, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 20, 2024

The narrative review aims to explore CRC pathogenesis by deciphering genetic-environmental interactions, analyzing the tumor microenvironment's role, and assessing treatment responses. These objectives seek enhance clinical decision-making improve patient care through a comprehensive understanding of disease. A from 2019 2024 on colorectal cancer (CRC) strategies was conducted. Systematic literature searches were performed PubMed, using CRC-related keywords ("Colorectal Neoplasms"[Mesh]) AND "Tumor Microenvironment"[Mesh]. Screening yielded 233 eligible studies, with 14 highly relevant ones included. PRISMA guidelines followed for transparency reproducibility. This spanning 2019-2024 shows diverse study designs (5 4 randomized controlled trials, 2 cohort 3 systematic reviews) varied sample sizes (from 4000 participants). Genetic mutations like KRAS BRAF are significant in pathogenesis, 8% exhibiting MMR proficiency. Immune cells paracrine signaling influential, therapeutic responses vary, limited efficacy reported certain combinations. highlights CRC's multifactorial nature complex dynamics. Integrating genetic, environmental, immune factors, personalized therapies pivotal efficacy. Continued research is crucial optimizing treatments improving outcomes, emphasizing need multifaceted, patient-tailored approaches management.

Language: Английский

Citations

0